July 2 (Reuters) - The U.S. Centers for Disease Control

and Prevention has accepted recommendations made by an advisory

panel in April on the use of respiratory syncytial virus

vaccines in adults aged between 50 and 59 years who are at an

increased risk of severe illness from the virus.

The panel of vaccine experts was fired in June by U.S.

Health Secretary Robert F Kennedy Jr.

The recommendations were also accepted by Kennedy, in the

absence of the director of the agency, the CDC's website showed

on Wednesday.

The CDC director typically signs off on the panel's

recommendations before they are implemented, but the agency does

not currently have one. President Donald Trump's nomination for

the post, Susan Monarez, is yet to be confirmed by the U.S.

Senate.

The U.S. Food and Drug Administration has approved three

vaccines for RSV - GSK's Arexvy, Moderna's ( MRNA )

mRESVIA and Pfizer's ( PFE ) Abrysvo.

(Reporting by Mariam Sunny in Bengaluru; Editing by Shinjini

Ganguli)